BRISTOL-MYERS SQUIBB COMPANY

NYSE: BMY (Bristol-Myers Squibb Company)

Last update: 15 Apr, 3:47PM

50.00

-1.34 (-2.61%)

  • 1D -2.61%
  • 5D -5.78%
  • 1M -15.55%
  • 6M -5.02%
  • YTD -11.96%
  • 1Y 11.48%
  • 5Y -20.08%
Previous Close 51.34
Open 51.22
Volume 12,044,332
Avg. Volume (3M) 12,662,462
Market Cap 101,737,996,288
Price / Earnings (Forward) 7.59
Price / Sales 2.15
Price / Book 6.40
52 Weeks Range
39.35 (-21%) — 63.33 (26%)
Earnings Date 24 Apr 2025
TTM Dividend Yield 4.84%
Profit Margin -18.53%
Operating Margin (TTM) 22.66%
Diluted EPS (TTM) -4.41
Quarterly Revenue Growth (YOY) 7.50%
Quarterly Earnings Growth (YOY) -95.90%
Total Debt/Equity (MRQ) 312.77%
Current Ratio (MRQ) 1.25
Operating Cash Flow (TTM) 15.19 B
Levered Free Cash Flow (TTM) 16.89 B
Return on Assets (TTM) 6.55%
Return on Equity (TTM) -38.95%

Market Trend

Short Term Medium Term
Industry Drug Manufacturers - General (US) Bearish Bullish
Drug Manufacturers - General (Global) Bearish Bullish
Stock Bristol-Myers Squibb Company Bearish Bullish

AIStockmoo Score

0.1
Analyst Consensus 1.0
Insider Activity -1.5
Price Volatility -1.0
Technical Moving Averages 2.5
Technical Oscillators -0.5
Average 0.10

Similar Stocks

Stock Market Cap DY P/E (TTM) P/B
BMY 102 B 4.84% - 6.40
JNJ 372 B 3.21% 17.19 4.77
ABBV 311 B 3.64% 72.57 90.53
PFE 130 B 7.37% 16.26 1.45
GSK 70 B 3.32% 21.65 4.19
LLY 794 B 0.61% 75.73 52.34

Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
Sector Healthcare
Industry Drug Manufacturers - General
Investment Style Large Value
% Held by Insiders 0.07%
% Held by Institutions 80.57%
52 Weeks Range
39.35 (-21%) — 63.33 (26%)
Price Target Range
54.00 (8%) — 68.00 (36%)
High 68.00 (Jefferies, 36.00%) Buy
Median 62.00 (24.00%)
Low 54.00 (UBS, 8.00%) Hold
Average 60.57 (21.14%)
Total 2 Buy, 5 Hold
Avg. Price @ Call 52.77
Firm Date Target Price Call Price @ Call
Cantor Fitzgerald 23 Apr 2025 55.00 (10.00%) Hold 50.00
22 Apr 2025 55.00 (10.00%) Hold 50.00
Jefferies 23 Apr 2025 68.00 (36.00%) Buy 50.00
Piper Sandler 22 Apr 2025 65.00 (30.00%) Buy 50.00
UBS 11 Apr 2025 54.00 (8.00%) Hold 50.71
Goldman Sachs 08 Apr 2025 55.00 (10.00%) Hold 53.07
Wells Fargo 07 Feb 2025 62.00 (24.00%) Hold 56.85
Citigroup 28 Jan 2025 65.00 (30.00%) Hold 58.76

No data within this time range.

  • 3M
Date Type Details
24 Apr 2025 Announcement Bristol Myers Squibb Reports First Quarter Financial Results for 2025
24 Apr 2025 CNBC Bristol Myers Squibb tops quarterly estimates, hikes outlook as drugmaker braces for tariffs
22 Apr 2025 Announcement Bristol Myers Squibb Announces Topline Results from Phase 3 ARISE Trial Evaluating Cobenfy (xanomeline and trospium chloride) as an Adjunctive Treatment to Atypical Antipsychotics in Adults with Schizophrenia
17 Apr 2025 Announcement U.S. Food and Drug Administration Updates CAMZYOS® (mavacamten) Label to Reduce Echocardiography Monitoring Requirements and Contraindications
15 Apr 2025 Announcement Optellum Announces Agreement with Bristol Myers Squibb to Leverage AI to Boost Early Lung Cancer Diagnosis
14 Apr 2025 Announcement Bristol Myers Squibb Provides Update on Phase 3 ODYSSEY-HCM Trial
11 Apr 2025 CNBC Trump's pharmaceutical tariffs could raise costs for patients, worsen drug shortages
11 Apr 2025 Announcement U.S. Food and Drug Administration Approves Opdivo® (nivolumab) plus Yervoy® (ipilimumab) as a First-Line Treatment for Unresectable or Metastatic Hepatocellular Carcinoma
09 Apr 2025 CNBC Pharmaceutical stocks rise as Trump pauses tariffs but not for China
08 Apr 2025 Announcement U.S. Food and Drug Administration Approves Opdivo® (nivolumab) plus Yervoy® (ipilimumab) as a Treatment for Patients with Previously Untreated Microsatellite Instability-High or Mismatch Repair Deficient Unresectable or Metastatic Colorectal Cancer¹
28 Mar 2025 Announcement Bristol Myers Squibb Receives Positive CHMP Opinion for Perioperative Regimen of Neoadjuvant Opdivo® (nivolumab) and Chemotherapy Followed by Surgery and Adjuvant Opdivo for Resectable Non-Small Cell Lung Cancer in Patients with Tumor Cell PD-L1...
28 Mar 2025 Announcement Bristol Myers Squibb Receives Positive CHMP Opinion for the Subcutaneous Formulation of Opdivo® (nivolumab) Across Multiple Solid Tumor Indications
20 Mar 2025 Announcement Cardurion Pharmaceuticals Appoints Karen Lewis as Chief People Officer
14 Mar 2025 Announcement Bristol Myers Squibb Receives Approval from the European Commission to Expand Use of CAR T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma
10 Mar 2025 Announcement 2seventy bio Enters into Definitive Agreement to be Acquired by Bristol Myers Squibb
08 Mar 2025 Announcement Bristol Myers Squibb Presents Late-Breaking Data from Phase 3 POETYK PsA-2 Trial Demonstrating Superiority of Sotyktu (deucravacitinib) Compared with Placebo in Adults with Psoriatic Arthritis
07 Mar 2025 Announcement Bristol Myers Squibb Receives European Commission Approval for Opdivo® (nivolumab) plus Yervoy® (ipilimumab) for the First-Line Treatment of Adult Patients with Unresectable or Advanced Hepatocellular Carcinoma
03 Mar 2025 Announcement Bristol Myers Squibb Announces Dividend
25 Feb 2025 Announcement Bristol Myers Squibb to Participate in Upcoming Investor Conferences
24 Feb 2025 Announcement U.S. Food and Drug Administration Accepts Bristol Myers Squibb’s Supplemental Biologics License Application for Opdivo® Plus Yervoy® for Patients with Unresectable or Metastatic Microsatellite Instability-High or Mismatch Repair Deficient...
20 Feb 2025 Announcement BioArctic's global license agreement with Bristol Myers Squibb for PyroGlutamate-amyloid-beta antibody program effective after antitrust clearance and closing
19 Feb 2025 Announcement Bristol Myers Squibb Announces Opdivo® Plus Chemotherapy as the First and Only Neoadjuvant-Only Immuno-Oncology Therapy to Demonstrate Statistically Significant and Clinically Meaningful Overall Survival in Resectable Non-Small Cell Lung Cancer
16 Feb 2025 Announcement New Five-Year Sotyktu (deucravacitinib) Data Show Consistent Safety and Durable Response Rates in Moderate-to-Severe Plaque Psoriasis
13 Feb 2025 Announcement Bristol Myers Squibb Provides Update on Phase 3 RELATIVITY-098 Trial
10 Feb 2025 Announcement Bristol Myers Squibb Announces Positive Topline Results for Breyanzi® (lisocabtagene maraleucel) in Adult Patients with Relapsed or Refractory Marginal Zone Lymphoma
10 Feb 2025 CNBC Trump is unlikely to end Medicare drug price talks — here's what that means for patients and pharma
06 Feb 2025 Announcement Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2024
06 Feb 2025 CNBC Bristol Myers Squibb plans $2 billion in cost cuts by 2027, issues weak guidance
31 Jan 2025 Announcement Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo® (nivolumab) plus Yervoy® (ipilimumab) as a First-Line Treatment Option for Adult Patients with Unresectable or Advanced Hepatocellular Carcinoma
31 Jan 2025 Announcement Bristol Myers Squibb Receives Positive CHMP Opinion for CAR T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma
Show more
TTM Dividend Yield 4.84%
5Y Average Dividend Yield 3.55%
Payout Ratio 59.84%
Expected Next Dividend Payment Aug 2025
Ex Date Announcement Date Payment Date Details
03 Jan 2025 11 Dec 2024 03 Feb 2025 0.62 Cash
04 Oct 2024 10 Sep 2024 01 Nov 2024 0.6 Cash
05 Jul 2024 18 Jun 2024 01 Aug 2024 0.6 Cash
04 Apr 2024 01 Mar 2024 01 May 2024 0.6 Cash
04 Jan 2024 06 Dec 2023 01 Feb 2024 0.6 Cash
05 Oct 2023 20 Sep 2023 01 Nov 2023 0.57 Cash
06 Jul 2023 14 Jun 2023 01 Aug 2023 0.57 Cash
06 Apr 2023 03 Mar 2023 01 May 2023 0.57 Cash
05 Jan 2023 08 Dec 2022 01 Feb 2023 0.57 Cash
06 Oct 2022 14 Sep 2022 01 Nov 2022 0.54 Cash
30 Jun 2022 15 Jun 2022 01 Aug 2022 0.54 Cash
31 Mar 2022 01 Mar 2022 02 May 2022 0.54 Cash
06 Jan 2022 13 Dec 2021 01 Feb 2022 0.54 Cash
30 Sep 2021 09 Sep 2021 01 Nov 2021 0.49 Cash
01 Jul 2021 17 Jun 2021 02 Aug 2021 0.49 Cash
31 Mar 2021 01 Mar 2021 03 May 2021 0.49 Cash
31 Dec 2020 10 Dec 2020 01 Feb 2021 0.49 Cash
01 Oct 2020 10 Sep 2020 02 Nov 2020 0.45 Cash
02 Jul 2020 11 Jun 2020 03 Aug 2020 0.45 Cash
02 Apr 2020 02 Mar 2020 01 May 2020 0.45 Cash
02 Jan 2020 06 Dec 2019 03 Feb 2020 0.45 Cash
03 Oct 2019 12 Sep 2019 01 Nov 2019 0.41 Cash
03 Jul 2019 14 Jun 2019 01 Aug 2019 0.41 Cash
04 Apr 2019 08 Mar 2019 01 May 2019 0.41 Cash
03 Jan 2019 07 Dec 2018 01 Feb 2019 0.41 Cash
04 Oct 2018 13 Sep 2018 01 Nov 2018 0.4 Cash
05 Jul 2018 15 Jun 2018 01 Aug 2018 0.4 Cash
05 Apr 2018 01 Mar 2018 01 May 2018 0.4 Cash
04 Jan 2018 07 Dec 2017 01 Feb 2018 0.4 Cash
05 Oct 2017 13 Sep 2017 01 Nov 2017 0.39 Cash
05 Jul 2017 13 Jun 2017 01 Aug 2017 0.39 Cash
05 Apr 2017 02 Mar 2017 01 May 2017 0.39 Cash
04 Jan 2017 08 Dec 2016 01 Feb 2017 0.39 Cash
05 Oct 2016 03 Aug 2016 01 Nov 2016 0.38 Cash
29 Jun 2016 07 Jun 2016 01 Aug 2016 0.38 Cash
30 Mar 2016 03 Mar 2016 02 May 2016 0.38 Cash
30 Dec 2015 08 Dec 2015 01 Feb 2016 0.38 Cash
30 Sep 2015 17 Sep 2015 02 Nov 2015 0.37 Cash
01 Jul 2015 16 Jun 2015 03 Aug 2015 0.37 Cash
01 Apr 2015 02 Mar 2015 01 May 2015 0.37 Cash
30 Dec 2014 09 Dec 2014 02 Feb 2015 0.37 Cash
01 Oct 2014 16 Sep 2014 03 Nov 2014 0.36 Cash
01 Jul 2014 17 Jun 2014 01 Aug 2014 0.36 Cash
02 Apr 2014 03 Mar 2014 01 May 2014 0.36 Cash
31 Dec 2013 19 Dec 2013 03 Feb 2014 0.36 Cash
02 Oct 2013 17 Sep 2013 01 Nov 2013 0.35 Cash
02 Jul 2013 19 Jun 2013 01 Aug 2013 0.35 Cash
Show more

Annual Dividend Yield

Year Annual Dividend ($) Frequency/Year Yield %
2025 0.620 1 1.24
2024 2.40 4 4.24
2023 2.28 4 4.44
2022 2.16 4 3.00
2021 1.96 4 3.14
2020 1.80 4 2.90
2019 1.64 4 2.56
2018 1.60 4 3.08
2017 1.56 4 2.55
2016 1.52 4 2.60
2015 1.48 4 2.15
2014 1.44 4 2.44
2013 0.700 2 1.32
Show more

The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.

Portfolio

AI Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2025 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No stocks matching your criteria